Everest Medicines announced that its licensing partner, Pfizer Inc. has received approval from the U.S. Food and Drug Administration for VELSIPITY™, an oral, once-daily, selective sphingosine-1-phosphate receptor modulator for adults with moderately to severely active ulcerative colitis.
